Objective:To observe the changes in insulin resistance in patients with gestational diabetes mellitus(GDM)based on the detection of serum microRNA-372-3p and glucose transporter protein 4(GLUT4)levels.Methods:We condu...Objective:To observe the changes in insulin resistance in patients with gestational diabetes mellitus(GDM)based on the detection of serum microRNA-372-3p and glucose transporter protein 4(GLUT4)levels.Methods:We conducted a retrospective cohort study of 42 patients who were diagnosed with GDM and hospitalized in our hospital during the period from January 2017 to December 2021 and another 42 patients who had normal pregnancy during the same period by collecting their clinical data.We analyzed their serum microRNA expression profiles and miR-372-3p levels to study the relationship between GDM and insulin resistance.Results:The relative expression of miR-372-3p in the serum of patients in the GDM group was significantly higher than that of patients in the control group,but the GLUT 4 level of the GDM group was significantly lower than that of the control group(P<0.05).Compared with the control group,the GDM group had significantly higher levels of fasting blood glucose(FBG),fasting insulin(FINS),2-hour postprandial blood glucose(2h-BG),total cholesterol(TC),triglyceride(TG),and homeostatic model assessment for insulin resistance(HOMA-IR)index but significantly lower homeostasis model assessment ofβ-cell function(HOMA-β)index(P<0.05).The relative expression of miR-372-3p in serum was independently and positively correlated with HOMA-IR,while the level of GLUT4 was independently and negatively correlated with HOMA-IR(P<0.05).Conclusion:Glycosylated hemoglobin test in the early stages of pregnancy(12–13 weeks of gestation)is important to ensure the health of pregnant women and fetuses.The screening and intervention for elevated glucose in pregnant women act as a guideline for the treatment of GDM.Patients with insulin resistance and related complications such as hyperinsulinemia and hypoglycemia should be given priority.展开更多
BACKGROUND Hepatocellular carcinoma(HCC)has been a pervasive malignancy throughout the world with elevated mortality.Efficient therapeutic targets are beneficial to treat and predict the disease.Currently,the exact mo...BACKGROUND Hepatocellular carcinoma(HCC)has been a pervasive malignancy throughout the world with elevated mortality.Efficient therapeutic targets are beneficial to treat and predict the disease.Currently,the exact molecular mechanisms leading to the progression of HCC are still unclear.Research has shown that the microRNA-142-3p level decreases in HCC,whereas bioinformatics analysis of the cancer genome atlas database shows the ASH1L expression increased among liver tumor tissues.In this paper,we will explore the effects and mechanisms of microRNA-142-3p and ASH1L affect the prognosis of HCC patients and HCC cell bioactivity,and the association between them.AIM To investigate the effects and mechanisms of microRNA-142-3p and ASH1L on the HCC cell bioactivity and prognosis of HCC patients.METHODS In this study,we grouped HCC patients according to their immunohistochemistry results of ASH1L with pathological tissues,and retrospectively analyzed the prognosis of HCC patients.Furthermore,explored the roles and mechanisms of microRNA-142-3p and ASH1L by cellular and animal experiments,which involved the following experimental methods:Immunohistochemical staining,western blot,quantitative real-time-polymerase chain reaction,flow cytometric analysis,tumor xenografts in nude mice,etc.The statistical methods involved in this study contained t-test,one-way analysis of variance,theχ^(2)test,the Kaplan-Meier approach and the log-rank test.RESULTS In this study,we found that HCC patients with high expression of ASH1L possess a more recurrence rate as well as a decreased overall survival rate.ASH1L promotes the tumorigenicity of HCC and microRNA-142-3p exhibits reduced expression in HCC tissues and interacts with ASH1L through targeting the ASH1L 3′untranslated region.Furthermore,microRNA-142-3p promotes apoptosis and inhibits proliferation,invasion,and migration of HCC cell lines in vitro via ASH1L.For the exploration mechanism,we found ASH1L may promote an immunosuppressive microenvironment in HCC and ASH1L affects the expression of the cell junction protein zonula occludens-1,which is potentially relevant to the immune system.CONCLUSION Loss function of microRNA-142-3p induces cancer progression and immune evasion through upregulation of ASH1L in HCC.Both microRNA-142-3p and ASH1L can feature as new biomarker for HCC in the future.展开更多
目的:检测miR-372-3p在膀胱癌组织和转染miR-372-3p mimics膀胱癌细胞中的表达,研究miR-372-3p对膀胱癌5637和T24细胞增殖、迁移与侵袭的影响。方法:采集2016年3月至2017年1月武汉中心医院收治的6例膀胱癌患者癌及癌旁组织(距离肿瘤边缘...目的:检测miR-372-3p在膀胱癌组织和转染miR-372-3p mimics膀胱癌细胞中的表达,研究miR-372-3p对膀胱癌5637和T24细胞增殖、迁移与侵袭的影响。方法:采集2016年3月至2017年1月武汉中心医院收治的6例膀胱癌患者癌及癌旁组织(距离肿瘤边缘>5 cm),q PCR检测膀胱癌及癌旁组织miR-372-3p表达。采用脂质体转染法将miR-372-3p mimics或者miRNC转入膀胱癌5637和T24细胞。用q PCR和Western blotting检测转染miR-372-3p mimics和miR-NC膀胱癌细胞miR-372-3p和ATAD2 m RNA和蛋白E-cadherin、N-cadherin蛋白的表达,流式细胞术检测细胞周期分布,MTT法和集落形成实验检测细胞增殖和集落形成能力,划痕实验和Transwell侵袭实验检测细胞的迁移和侵袭能力。结果:膀胱癌组织miR-372-3p m RNA的表达显著低于癌旁组织(0.65±0.56 vs 1.76±0.34,P<0.01)。和转染miR-NC膀胱癌细胞相比,转染miR-372-3p mimics膀胱癌细胞的miR-372-3p m RNA表达显著增加,ATAD2 m RNA和蛋白的表达显著降低,E-cadherin蛋白表达上调,N-cadherin蛋白表达下调,细胞周期明显阻滞,细胞集落形成和增殖能力显著降低,细胞迁移数和侵袭数减少。结论:miR-372-3p的低表达可能与膀胱癌的发生发展有关,其通过靶向调控ATAD2抑制膀胱癌细胞的增殖、迁移和侵袭能力,可能成为膀胱癌生物治疗的新靶标。展开更多
基金supported by the following projects:Youth Science and Technology Fund of Affiliated Hospital of Hebei University(2017Q024)Baoding City Science and Technology Plan Project(2041zf295),and Hebei University Medical Subject Cultivation Project(2022b03).
文摘Objective:To observe the changes in insulin resistance in patients with gestational diabetes mellitus(GDM)based on the detection of serum microRNA-372-3p and glucose transporter protein 4(GLUT4)levels.Methods:We conducted a retrospective cohort study of 42 patients who were diagnosed with GDM and hospitalized in our hospital during the period from January 2017 to December 2021 and another 42 patients who had normal pregnancy during the same period by collecting their clinical data.We analyzed their serum microRNA expression profiles and miR-372-3p levels to study the relationship between GDM and insulin resistance.Results:The relative expression of miR-372-3p in the serum of patients in the GDM group was significantly higher than that of patients in the control group,but the GLUT 4 level of the GDM group was significantly lower than that of the control group(P<0.05).Compared with the control group,the GDM group had significantly higher levels of fasting blood glucose(FBG),fasting insulin(FINS),2-hour postprandial blood glucose(2h-BG),total cholesterol(TC),triglyceride(TG),and homeostatic model assessment for insulin resistance(HOMA-IR)index but significantly lower homeostasis model assessment ofβ-cell function(HOMA-β)index(P<0.05).The relative expression of miR-372-3p in serum was independently and positively correlated with HOMA-IR,while the level of GLUT4 was independently and negatively correlated with HOMA-IR(P<0.05).Conclusion:Glycosylated hemoglobin test in the early stages of pregnancy(12–13 weeks of gestation)is important to ensure the health of pregnant women and fetuses.The screening and intervention for elevated glucose in pregnant women act as a guideline for the treatment of GDM.Patients with insulin resistance and related complications such as hyperinsulinemia and hypoglycemia should be given priority.
基金Supported by the Haihe Laboratory of Cell Ecosystem Innovation Fund,No.22HHXBJC00001the Key Discipline Special Project of Tianjin Municipal Health Commission,No.TJWJ2022XK016.
文摘BACKGROUND Hepatocellular carcinoma(HCC)has been a pervasive malignancy throughout the world with elevated mortality.Efficient therapeutic targets are beneficial to treat and predict the disease.Currently,the exact molecular mechanisms leading to the progression of HCC are still unclear.Research has shown that the microRNA-142-3p level decreases in HCC,whereas bioinformatics analysis of the cancer genome atlas database shows the ASH1L expression increased among liver tumor tissues.In this paper,we will explore the effects and mechanisms of microRNA-142-3p and ASH1L affect the prognosis of HCC patients and HCC cell bioactivity,and the association between them.AIM To investigate the effects and mechanisms of microRNA-142-3p and ASH1L on the HCC cell bioactivity and prognosis of HCC patients.METHODS In this study,we grouped HCC patients according to their immunohistochemistry results of ASH1L with pathological tissues,and retrospectively analyzed the prognosis of HCC patients.Furthermore,explored the roles and mechanisms of microRNA-142-3p and ASH1L by cellular and animal experiments,which involved the following experimental methods:Immunohistochemical staining,western blot,quantitative real-time-polymerase chain reaction,flow cytometric analysis,tumor xenografts in nude mice,etc.The statistical methods involved in this study contained t-test,one-way analysis of variance,theχ^(2)test,the Kaplan-Meier approach and the log-rank test.RESULTS In this study,we found that HCC patients with high expression of ASH1L possess a more recurrence rate as well as a decreased overall survival rate.ASH1L promotes the tumorigenicity of HCC and microRNA-142-3p exhibits reduced expression in HCC tissues and interacts with ASH1L through targeting the ASH1L 3′untranslated region.Furthermore,microRNA-142-3p promotes apoptosis and inhibits proliferation,invasion,and migration of HCC cell lines in vitro via ASH1L.For the exploration mechanism,we found ASH1L may promote an immunosuppressive microenvironment in HCC and ASH1L affects the expression of the cell junction protein zonula occludens-1,which is potentially relevant to the immune system.CONCLUSION Loss function of microRNA-142-3p induces cancer progression and immune evasion through upregulation of ASH1L in HCC.Both microRNA-142-3p and ASH1L can feature as new biomarker for HCC in the future.
文摘目的:检测miR-372-3p在膀胱癌组织和转染miR-372-3p mimics膀胱癌细胞中的表达,研究miR-372-3p对膀胱癌5637和T24细胞增殖、迁移与侵袭的影响。方法:采集2016年3月至2017年1月武汉中心医院收治的6例膀胱癌患者癌及癌旁组织(距离肿瘤边缘>5 cm),q PCR检测膀胱癌及癌旁组织miR-372-3p表达。采用脂质体转染法将miR-372-3p mimics或者miRNC转入膀胱癌5637和T24细胞。用q PCR和Western blotting检测转染miR-372-3p mimics和miR-NC膀胱癌细胞miR-372-3p和ATAD2 m RNA和蛋白E-cadherin、N-cadherin蛋白的表达,流式细胞术检测细胞周期分布,MTT法和集落形成实验检测细胞增殖和集落形成能力,划痕实验和Transwell侵袭实验检测细胞的迁移和侵袭能力。结果:膀胱癌组织miR-372-3p m RNA的表达显著低于癌旁组织(0.65±0.56 vs 1.76±0.34,P<0.01)。和转染miR-NC膀胱癌细胞相比,转染miR-372-3p mimics膀胱癌细胞的miR-372-3p m RNA表达显著增加,ATAD2 m RNA和蛋白的表达显著降低,E-cadherin蛋白表达上调,N-cadherin蛋白表达下调,细胞周期明显阻滞,细胞集落形成和增殖能力显著降低,细胞迁移数和侵袭数减少。结论:miR-372-3p的低表达可能与膀胱癌的发生发展有关,其通过靶向调控ATAD2抑制膀胱癌细胞的增殖、迁移和侵袭能力,可能成为膀胱癌生物治疗的新靶标。
